FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver
FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver Xinqiang Huang , Chaofeng Yang , Yongde Luo , Chengliu Jin , Fen Wang and Wallace L. McKeehan From the Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M...
Gespeichert in:
Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2007-10, Vol.56 (10), p.2501-2510 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2510 |
---|---|
container_issue | 10 |
container_start_page | 2501 |
container_title | Diabetes (New York, N.Y.) |
container_volume | 56 |
creator | Huang, Xinqiang Yang, Chaofeng Luo, Yongde Jin, Chengliu Wang, Fen McKeehan, Wallace L |
description | FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver
Xinqiang Huang ,
Chaofeng Yang ,
Yongde Luo ,
Chengliu Jin ,
Fen Wang and
Wallace L. McKeehan
From the Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center,
Houston, Texas
Address correspondence and reprint requests to Wallace L. McKeehan, PhD, Center for Cancer and Stem Cell Biology, Institute
of Biosciences and Technology, Texas A&M Health Science Center, 2121 W. Holcombe Blvd., Houston, TX 77030. E-mail: wmckeehan{at}ibt.tamhsc.edu
Abstract
OBJECTIVE— Fibroblast growth factor (FGF) family signaling largely controls cellular homeostasis through short-range intercell paracrine
communication. Recently FGF15/19, 21, and 23 have been implicated in endocrine control of metabolic homeostasis. The identity
and location of the FGF receptor isotypes that mediate these effects are unclear. The objective was to determine the role
of FGFR4, an isotype that has been proposed to mediate an ileal FGF15/19 to hepatocyte FGFR4 axis in cholesterol homeostasis,
in metabolic homeostasis in vivo.
RESEARCH DESIGN AND METHODS— FGFR4 −/− mice—mice overexpressing constitutively active hepatic FGFR4—and FGFR4 −/− with constitutively active hepatic FGFR4 restored in the liver were subjected to a normal and a chronic high-fat diet sufficient
to result in obesity. Systemic and liver-specific metabolic phenotypes were then characterized.
RESULTS— FGFR4-deficient mice on a normal diet exhibited features of metabolic syndrome that include increased mass of white adipose
tissue, hyperlipidemia, glucose intolerance, and insulin resistance, in addition to hypercholesterolemia. Surprisingly, the
FGFR4 deficiency alleviated high-fat diet–induced fatty liver in obese mice, which is also a correlate of metabolic syndrome.
Restoration of FGFR4, specifically in hepatocytes of FGFR4-deficient mice, decreased plasma lipid levels and restored the
high-fat diet–induced fatty liver but failed to restore glucose tolerance and sensitivity to insulin.
CONCLUSIONS— FGFR4 plays essential roles in systemic lipid and glucose homeostasis. FGFR4 activity in hepatocytes that normally serves
to prevent systemic hyperlipidemia paradoxically underlies the fatty liver disease associated with chronic high-fat intake
and obesity.
FGF, fibroblast growth factor
FXR, farnesoid X receptor
G6Pase, glucose-6-phosphatase
NAFLD, nonalcoholic fatty liver disease
PP |
doi_str_mv | 10.2337/db07-0648 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68328360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A170036748</galeid><sourcerecordid>A170036748</sourcerecordid><originalsourceid>FETCH-LOGICAL-c627t-c3c87d9cdb0be2d70ad3a43b6e6d2e73e726e8d2cd23a90daf4780a6ac198cd13</originalsourceid><addsrcrecordid>eNpt0t1q2zAUB3AxNta028VeYJjBCoO504cj2ZclW9JAoKOssDshS8euiiOnktwtd3uHveGeZPISCB1BFxLid8TR4Y_QG4IvKGPik6mxyDEvymdoQipW5YyK78_RBGNCcyIqcYJOQ7jHGPO0XqITIjgvaMEmqJkv5jdF9tXDI7gYsqvtBnxnN9bA2qpMOZMtXRg667IbCDZE5TRk9RCzW2dGCanGtnf5XMXss4X459fvpTODBpOlq7jNVvYR_Cv0olFdgNf7_Qzdzr98m13lq-vFcna5yjWnIuaa6VKYSqcP1UCNwMowVbCaAzcUBANBOZSGakOZqrBRTSFKrLjSpCq1IewMne_e3fj-YYAQ5doGDV2nHPRDkLxktGQcJ_juP3jfD96l3iQlvBBClFVC-Q61qgNpXdNHr3QLDrzqegeNTdeXRGDMuCjK5C-O-LTGYeqjBR-eFCQT4Wds1RCCLBerpzY_ZnXfddCCTGOcXR99W_s-BA-N3Hi7Vn4rCZZjbOQYGznGJtm3-2kM9RrMQe5zksD7PVBBq67xKQY2HFxFpoKRaXIfd-4uZeKH9SCNVTVECIfDlP_rYIoJ-wsPZ9ci</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216477789</pqid></control><display><type>article</type><title>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Huang, Xinqiang ; Yang, Chaofeng ; Luo, Yongde ; Jin, Chengliu ; Wang, Fen ; McKeehan, Wallace L</creator><creatorcontrib>Huang, Xinqiang ; Yang, Chaofeng ; Luo, Yongde ; Jin, Chengliu ; Wang, Fen ; McKeehan, Wallace L</creatorcontrib><description>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver
Xinqiang Huang ,
Chaofeng Yang ,
Yongde Luo ,
Chengliu Jin ,
Fen Wang and
Wallace L. McKeehan
From the Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center,
Houston, Texas
Address correspondence and reprint requests to Wallace L. McKeehan, PhD, Center for Cancer and Stem Cell Biology, Institute
of Biosciences and Technology, Texas A&M Health Science Center, 2121 W. Holcombe Blvd., Houston, TX 77030. E-mail: wmckeehan{at}ibt.tamhsc.edu
Abstract
OBJECTIVE— Fibroblast growth factor (FGF) family signaling largely controls cellular homeostasis through short-range intercell paracrine
communication. Recently FGF15/19, 21, and 23 have been implicated in endocrine control of metabolic homeostasis. The identity
and location of the FGF receptor isotypes that mediate these effects are unclear. The objective was to determine the role
of FGFR4, an isotype that has been proposed to mediate an ileal FGF15/19 to hepatocyte FGFR4 axis in cholesterol homeostasis,
in metabolic homeostasis in vivo.
RESEARCH DESIGN AND METHODS— FGFR4 −/− mice—mice overexpressing constitutively active hepatic FGFR4—and FGFR4 −/− with constitutively active hepatic FGFR4 restored in the liver were subjected to a normal and a chronic high-fat diet sufficient
to result in obesity. Systemic and liver-specific metabolic phenotypes were then characterized.
RESULTS— FGFR4-deficient mice on a normal diet exhibited features of metabolic syndrome that include increased mass of white adipose
tissue, hyperlipidemia, glucose intolerance, and insulin resistance, in addition to hypercholesterolemia. Surprisingly, the
FGFR4 deficiency alleviated high-fat diet–induced fatty liver in obese mice, which is also a correlate of metabolic syndrome.
Restoration of FGFR4, specifically in hepatocytes of FGFR4-deficient mice, decreased plasma lipid levels and restored the
high-fat diet–induced fatty liver but failed to restore glucose tolerance and sensitivity to insulin.
CONCLUSIONS— FGFR4 plays essential roles in systemic lipid and glucose homeostasis. FGFR4 activity in hepatocytes that normally serves
to prevent systemic hyperlipidemia paradoxically underlies the fatty liver disease associated with chronic high-fat intake
and obesity.
FGF, fibroblast growth factor
FXR, farnesoid X receptor
G6Pase, glucose-6-phosphatase
NAFLD, nonalcoholic fatty liver disease
PPAR, peroxisome proliferator–activated receptor
SCD, stearoyl-CoA desaturase
Footnotes
Published ahead of print at http://diabetes.diabetesjournals.org on 30 July 2007. DOI: 10.2337/db07-0648.
Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-0648 .
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Accepted July 18, 2007.
Received May 14, 2007.
DIABETES</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db07-0648</identifier><identifier>PMID: 17664243</identifier><identifier>CODEN: DIAEAZ</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Acids ; Adipose Tissue - pathology ; Animals ; Bile ; Biological and medical sciences ; Blood Glucose - metabolism ; Body fat ; Body Weight ; Cholesterol ; Diabetes ; Diabetes. Impaired glucose tolerance ; Diet ; Dietary Fats - adverse effects ; Disorders of blood lipids. Hyperlipoproteinemia ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Fatty liver ; Fatty Liver - genetics ; Fatty Liver - metabolism ; Fatty Liver - pathology ; Fibroblast growth factors ; Fibroblasts ; Gastroenterology. Liver. Pancreas. Abdomen ; Gene Expression Regulation ; Glucose ; Glucose - metabolism ; Growth factors ; Health aspects ; Heparan sulfate ; Homeostasis ; Hyperlipidemia ; Hyperlipidemias - genetics ; Hyperlipidemias - prevention & control ; Insulin - blood ; Insulin Resistance ; Lipids ; Lipids - physiology ; Liver - anatomy & histology ; Liver - pathology ; Liver - physiopathology ; Liver diseases ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Medical sciences ; Metabolic diseases ; Metabolic syndrome ; Mice ; Mice, Knockout ; Mice, Transgenic ; Nutrition research ; Obesity ; Organ Size ; Other diseases. Semiology ; Prevention ; Receptor, Fibroblast Growth Factor, Type 4 - deficiency ; Receptor, Fibroblast Growth Factor, Type 4 - genetics ; Receptor, Fibroblast Growth Factor, Type 4 - physiology ; Research design ; RNA, Messenger - genetics</subject><ispartof>Diabetes (New York, N.Y.), 2007-10, Vol.56 (10), p.2501-2510</ispartof><rights>2007 INIST-CNRS</rights><rights>COPYRIGHT 2007 American Diabetes Association</rights><rights>Copyright American Diabetes Association Oct 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c627t-c3c87d9cdb0be2d70ad3a43b6e6d2e73e726e8d2cd23a90daf4780a6ac198cd13</citedby><cites>FETCH-LOGICAL-c627t-c3c87d9cdb0be2d70ad3a43b6e6d2e73e726e8d2cd23a90daf4780a6ac198cd13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19157315$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17664243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Xinqiang</creatorcontrib><creatorcontrib>Yang, Chaofeng</creatorcontrib><creatorcontrib>Luo, Yongde</creatorcontrib><creatorcontrib>Jin, Chengliu</creatorcontrib><creatorcontrib>Wang, Fen</creatorcontrib><creatorcontrib>McKeehan, Wallace L</creatorcontrib><title>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver</title><title>Diabetes (New York, N.Y.)</title><addtitle>Diabetes</addtitle><description>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver
Xinqiang Huang ,
Chaofeng Yang ,
Yongde Luo ,
Chengliu Jin ,
Fen Wang and
Wallace L. McKeehan
From the Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center,
Houston, Texas
Address correspondence and reprint requests to Wallace L. McKeehan, PhD, Center for Cancer and Stem Cell Biology, Institute
of Biosciences and Technology, Texas A&M Health Science Center, 2121 W. Holcombe Blvd., Houston, TX 77030. E-mail: wmckeehan{at}ibt.tamhsc.edu
Abstract
OBJECTIVE— Fibroblast growth factor (FGF) family signaling largely controls cellular homeostasis through short-range intercell paracrine
communication. Recently FGF15/19, 21, and 23 have been implicated in endocrine control of metabolic homeostasis. The identity
and location of the FGF receptor isotypes that mediate these effects are unclear. The objective was to determine the role
of FGFR4, an isotype that has been proposed to mediate an ileal FGF15/19 to hepatocyte FGFR4 axis in cholesterol homeostasis,
in metabolic homeostasis in vivo.
RESEARCH DESIGN AND METHODS— FGFR4 −/− mice—mice overexpressing constitutively active hepatic FGFR4—and FGFR4 −/− with constitutively active hepatic FGFR4 restored in the liver were subjected to a normal and a chronic high-fat diet sufficient
to result in obesity. Systemic and liver-specific metabolic phenotypes were then characterized.
RESULTS— FGFR4-deficient mice on a normal diet exhibited features of metabolic syndrome that include increased mass of white adipose
tissue, hyperlipidemia, glucose intolerance, and insulin resistance, in addition to hypercholesterolemia. Surprisingly, the
FGFR4 deficiency alleviated high-fat diet–induced fatty liver in obese mice, which is also a correlate of metabolic syndrome.
Restoration of FGFR4, specifically in hepatocytes of FGFR4-deficient mice, decreased plasma lipid levels and restored the
high-fat diet–induced fatty liver but failed to restore glucose tolerance and sensitivity to insulin.
CONCLUSIONS— FGFR4 plays essential roles in systemic lipid and glucose homeostasis. FGFR4 activity in hepatocytes that normally serves
to prevent systemic hyperlipidemia paradoxically underlies the fatty liver disease associated with chronic high-fat intake
and obesity.
FGF, fibroblast growth factor
FXR, farnesoid X receptor
G6Pase, glucose-6-phosphatase
NAFLD, nonalcoholic fatty liver disease
PPAR, peroxisome proliferator–activated receptor
SCD, stearoyl-CoA desaturase
Footnotes
Published ahead of print at http://diabetes.diabetesjournals.org on 30 July 2007. DOI: 10.2337/db07-0648.
Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-0648 .
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Accepted July 18, 2007.
Received May 14, 2007.
DIABETES</description><subject>Acids</subject><subject>Adipose Tissue - pathology</subject><subject>Animals</subject><subject>Bile</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - metabolism</subject><subject>Body fat</subject><subject>Body Weight</subject><subject>Cholesterol</subject><subject>Diabetes</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diet</subject><subject>Dietary Fats - adverse effects</subject><subject>Disorders of blood lipids. Hyperlipoproteinemia</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Fatty liver</subject><subject>Fatty Liver - genetics</subject><subject>Fatty Liver - metabolism</subject><subject>Fatty Liver - pathology</subject><subject>Fibroblast growth factors</subject><subject>Fibroblasts</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gene Expression Regulation</subject><subject>Glucose</subject><subject>Glucose - metabolism</subject><subject>Growth factors</subject><subject>Health aspects</subject><subject>Heparan sulfate</subject><subject>Homeostasis</subject><subject>Hyperlipidemia</subject><subject>Hyperlipidemias - genetics</subject><subject>Hyperlipidemias - prevention & control</subject><subject>Insulin - blood</subject><subject>Insulin Resistance</subject><subject>Lipids</subject><subject>Lipids - physiology</subject><subject>Liver - anatomy & histology</subject><subject>Liver - pathology</subject><subject>Liver - physiopathology</subject><subject>Liver diseases</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Metabolic syndrome</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Mice, Transgenic</subject><subject>Nutrition research</subject><subject>Obesity</subject><subject>Organ Size</subject><subject>Other diseases. Semiology</subject><subject>Prevention</subject><subject>Receptor, Fibroblast Growth Factor, Type 4 - deficiency</subject><subject>Receptor, Fibroblast Growth Factor, Type 4 - genetics</subject><subject>Receptor, Fibroblast Growth Factor, Type 4 - physiology</subject><subject>Research design</subject><subject>RNA, Messenger - genetics</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0t1q2zAUB3AxNta028VeYJjBCoO504cj2ZclW9JAoKOssDshS8euiiOnktwtd3uHveGeZPISCB1BFxLid8TR4Y_QG4IvKGPik6mxyDEvymdoQipW5YyK78_RBGNCcyIqcYJOQ7jHGPO0XqITIjgvaMEmqJkv5jdF9tXDI7gYsqvtBnxnN9bA2qpMOZMtXRg667IbCDZE5TRk9RCzW2dGCanGtnf5XMXss4X459fvpTODBpOlq7jNVvYR_Cv0olFdgNf7_Qzdzr98m13lq-vFcna5yjWnIuaa6VKYSqcP1UCNwMowVbCaAzcUBANBOZSGakOZqrBRTSFKrLjSpCq1IewMne_e3fj-YYAQ5doGDV2nHPRDkLxktGQcJ_juP3jfD96l3iQlvBBClFVC-Q61qgNpXdNHr3QLDrzqegeNTdeXRGDMuCjK5C-O-LTGYeqjBR-eFCQT4Wds1RCCLBerpzY_ZnXfddCCTGOcXR99W_s-BA-N3Hi7Vn4rCZZjbOQYGznGJtm3-2kM9RrMQe5zksD7PVBBq67xKQY2HFxFpoKRaXIfd-4uZeKH9SCNVTVECIfDlP_rYIoJ-wsPZ9ci</recordid><startdate>20071001</startdate><enddate>20071001</enddate><creator>Huang, Xinqiang</creator><creator>Yang, Chaofeng</creator><creator>Luo, Yongde</creator><creator>Jin, Chengliu</creator><creator>Wang, Fen</creator><creator>McKeehan, Wallace L</creator><general>American Diabetes Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8GL</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20071001</creationdate><title>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver</title><author>Huang, Xinqiang ; Yang, Chaofeng ; Luo, Yongde ; Jin, Chengliu ; Wang, Fen ; McKeehan, Wallace L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c627t-c3c87d9cdb0be2d70ad3a43b6e6d2e73e726e8d2cd23a90daf4780a6ac198cd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Acids</topic><topic>Adipose Tissue - pathology</topic><topic>Animals</topic><topic>Bile</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - metabolism</topic><topic>Body fat</topic><topic>Body Weight</topic><topic>Cholesterol</topic><topic>Diabetes</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diet</topic><topic>Dietary Fats - adverse effects</topic><topic>Disorders of blood lipids. Hyperlipoproteinemia</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Fatty liver</topic><topic>Fatty Liver - genetics</topic><topic>Fatty Liver - metabolism</topic><topic>Fatty Liver - pathology</topic><topic>Fibroblast growth factors</topic><topic>Fibroblasts</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gene Expression Regulation</topic><topic>Glucose</topic><topic>Glucose - metabolism</topic><topic>Growth factors</topic><topic>Health aspects</topic><topic>Heparan sulfate</topic><topic>Homeostasis</topic><topic>Hyperlipidemia</topic><topic>Hyperlipidemias - genetics</topic><topic>Hyperlipidemias - prevention & control</topic><topic>Insulin - blood</topic><topic>Insulin Resistance</topic><topic>Lipids</topic><topic>Lipids - physiology</topic><topic>Liver - anatomy & histology</topic><topic>Liver - pathology</topic><topic>Liver - physiopathology</topic><topic>Liver diseases</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Metabolic syndrome</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Mice, Transgenic</topic><topic>Nutrition research</topic><topic>Obesity</topic><topic>Organ Size</topic><topic>Other diseases. Semiology</topic><topic>Prevention</topic><topic>Receptor, Fibroblast Growth Factor, Type 4 - deficiency</topic><topic>Receptor, Fibroblast Growth Factor, Type 4 - genetics</topic><topic>Receptor, Fibroblast Growth Factor, Type 4 - physiology</topic><topic>Research design</topic><topic>RNA, Messenger - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Xinqiang</creatorcontrib><creatorcontrib>Yang, Chaofeng</creatorcontrib><creatorcontrib>Luo, Yongde</creatorcontrib><creatorcontrib>Jin, Chengliu</creatorcontrib><creatorcontrib>Wang, Fen</creatorcontrib><creatorcontrib>McKeehan, Wallace L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: High School</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Xinqiang</au><au>Yang, Chaofeng</au><au>Luo, Yongde</au><au>Jin, Chengliu</au><au>Wang, Fen</au><au>McKeehan, Wallace L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><addtitle>Diabetes</addtitle><date>2007-10-01</date><risdate>2007</risdate><volume>56</volume><issue>10</issue><spage>2501</spage><epage>2510</epage><pages>2501-2510</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><coden>DIAEAZ</coden><abstract>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver
Xinqiang Huang ,
Chaofeng Yang ,
Yongde Luo ,
Chengliu Jin ,
Fen Wang and
Wallace L. McKeehan
From the Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center,
Houston, Texas
Address correspondence and reprint requests to Wallace L. McKeehan, PhD, Center for Cancer and Stem Cell Biology, Institute
of Biosciences and Technology, Texas A&M Health Science Center, 2121 W. Holcombe Blvd., Houston, TX 77030. E-mail: wmckeehan{at}ibt.tamhsc.edu
Abstract
OBJECTIVE— Fibroblast growth factor (FGF) family signaling largely controls cellular homeostasis through short-range intercell paracrine
communication. Recently FGF15/19, 21, and 23 have been implicated in endocrine control of metabolic homeostasis. The identity
and location of the FGF receptor isotypes that mediate these effects are unclear. The objective was to determine the role
of FGFR4, an isotype that has been proposed to mediate an ileal FGF15/19 to hepatocyte FGFR4 axis in cholesterol homeostasis,
in metabolic homeostasis in vivo.
RESEARCH DESIGN AND METHODS— FGFR4 −/− mice—mice overexpressing constitutively active hepatic FGFR4—and FGFR4 −/− with constitutively active hepatic FGFR4 restored in the liver were subjected to a normal and a chronic high-fat diet sufficient
to result in obesity. Systemic and liver-specific metabolic phenotypes were then characterized.
RESULTS— FGFR4-deficient mice on a normal diet exhibited features of metabolic syndrome that include increased mass of white adipose
tissue, hyperlipidemia, glucose intolerance, and insulin resistance, in addition to hypercholesterolemia. Surprisingly, the
FGFR4 deficiency alleviated high-fat diet–induced fatty liver in obese mice, which is also a correlate of metabolic syndrome.
Restoration of FGFR4, specifically in hepatocytes of FGFR4-deficient mice, decreased plasma lipid levels and restored the
high-fat diet–induced fatty liver but failed to restore glucose tolerance and sensitivity to insulin.
CONCLUSIONS— FGFR4 plays essential roles in systemic lipid and glucose homeostasis. FGFR4 activity in hepatocytes that normally serves
to prevent systemic hyperlipidemia paradoxically underlies the fatty liver disease associated with chronic high-fat intake
and obesity.
FGF, fibroblast growth factor
FXR, farnesoid X receptor
G6Pase, glucose-6-phosphatase
NAFLD, nonalcoholic fatty liver disease
PPAR, peroxisome proliferator–activated receptor
SCD, stearoyl-CoA desaturase
Footnotes
Published ahead of print at http://diabetes.diabetesjournals.org on 30 July 2007. DOI: 10.2337/db07-0648.
Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-0648 .
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Accepted July 18, 2007.
Received May 14, 2007.
DIABETES</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>17664243</pmid><doi>10.2337/db07-0648</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0012-1797 |
ispartof | Diabetes (New York, N.Y.), 2007-10, Vol.56 (10), p.2501-2510 |
issn | 0012-1797 1939-327X |
language | eng |
recordid | cdi_proquest_miscellaneous_68328360 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Acids Adipose Tissue - pathology Animals Bile Biological and medical sciences Blood Glucose - metabolism Body fat Body Weight Cholesterol Diabetes Diabetes. Impaired glucose tolerance Diet Dietary Fats - adverse effects Disorders of blood lipids. Hyperlipoproteinemia Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Fatty liver Fatty Liver - genetics Fatty Liver - metabolism Fatty Liver - pathology Fibroblast growth factors Fibroblasts Gastroenterology. Liver. Pancreas. Abdomen Gene Expression Regulation Glucose Glucose - metabolism Growth factors Health aspects Heparan sulfate Homeostasis Hyperlipidemia Hyperlipidemias - genetics Hyperlipidemias - prevention & control Insulin - blood Insulin Resistance Lipids Lipids - physiology Liver - anatomy & histology Liver - pathology Liver - physiopathology Liver diseases Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences Metabolic diseases Metabolic syndrome Mice Mice, Knockout Mice, Transgenic Nutrition research Obesity Organ Size Other diseases. Semiology Prevention Receptor, Fibroblast Growth Factor, Type 4 - deficiency Receptor, Fibroblast Growth Factor, Type 4 - genetics Receptor, Fibroblast Growth Factor, Type 4 - physiology Research design RNA, Messenger - genetics |
title | FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T14%3A33%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FGFR4%20Prevents%20Hyperlipidemia%20and%20Insulin%20Resistance%20but%20Underlies%20High-Fat%20Diet%E2%80%93Induced%20Fatty%20Liver&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=Huang,%20Xinqiang&rft.date=2007-10-01&rft.volume=56&rft.issue=10&rft.spage=2501&rft.epage=2510&rft.pages=2501-2510&rft.issn=0012-1797&rft.eissn=1939-327X&rft.coden=DIAEAZ&rft_id=info:doi/10.2337/db07-0648&rft_dat=%3Cgale_proqu%3EA170036748%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216477789&rft_id=info:pmid/17664243&rft_galeid=A170036748&rfr_iscdi=true |